RecruitingNCT06958107
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
Studying Bone sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- Johann Hsu, MDWake Forest University Health Sciences
- Intervention
- Non-Metastatic and Resectable(other)
- Enrollment
- 300 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2030
Study locations (2)
- Levine Cancer Institute, Charlotte, North Carolina, United States
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Collaborators
Paula Takacs Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06958107 on ClinicalTrials.govOther trials for Bone sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07479732Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaPeking University People's Hospital
- RECRUITINGPHASE1NCT07222735Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory SarcomasSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07359053MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced SarcomaShanghai 6th People's Hospital
- RECRUITINGPHASE2NCT06939855QL1706 in the Treatment of Advanced Bone and Soft Tissue SarcomaSun Yat-sen University
- RECRUITINGNCT07215611Financial Toxicity in Patients With Resected Soft Tissue and Bone SarcomasM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07066982Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasEssen Biotech
- RECRUITINGNANCT06796543Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone SarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGPHASE1, PHASE2NCT06709495Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasDavid S Shulman, MD